Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30843927 | 1.00 | SIGMAR1 (0.36) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL31441279 | 0.83 | CYP11B2 (0.42) | MAPT | |
| SCHEMBL12543442 | 0.81 | SIGMAR1 (0.46) | SIGMAR1NPC1RAB9AMEN1KMT2A | |
| SCHEMBL1666017 | 0.73 | — | — | |
| SCHEMBL31006068 | 0.72 | KDM4E (0.32) | MAPTKDM4EGAALMNAP2RX4 | |
| SCHEMBL7041384 | 0.72 | P2RX4 (0.35) | LMNAP2RX4 | |
| SCHEMBL2263869 | 0.72 | KDM4E (0.32) | MAPTKDM4EGAALMNAP2RX4 | |
| SCHEMBL3541130 | 0.72 | LMNA (0.34) | LMNAP2RX4 | |
| SCHEMBL3336306 | 0.72 | SCN9A (0.39) | NPC1RAB9AMEN1KMT2ANPSR1 | |
| SCHEMBL30081007 | 0.70 | P2RX4 (0.40) | NPSR1LMNASMN1; SMN2P2RX4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1265583-A | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-09-06 | — | — | CN | claimed |
| CN-112841478-A | Plant beverage for improving sleep and preparation method thereof | 陕西健驰生物药业有限公司 | 2021-05-28 | — | — | CN | disclosed |
| CN-109431668-A | For curing fat intragastric device | 西纳兹医疗股份有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-105263439-B | Intragastric device for treating obesity | 西纳兹医疗股份有限公司 | 2018-11-23 | — | — | CN | disclosed |
| US-9701617-B2 | Process for producing diamines and polyamines of the diphenylmethane series | COVESTRO DEUTSCHLAND AG (DE) | 2017-07-11 | — | — | US | disclosed |
| EP-2103595-B1 | Method for producing di and polyamines of diphenylmethane series | COVESTRO DEUTSCHLAND AG (DE) | 2017-04-19 | — | — | EP | disclosed |
| CN-106103425-A | Diacylglycerol acyltransferase 2 inhibitors for the treatment of metabolic and related disorders | 辉瑞公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-105263439-A | Intragastric device for treating obesity | SYNERZ MEDICAL INC | 2016-01-20 | — | — | CN | disclosed |
| US-8557988-B2 | Emissive transition-metal complexes with both carbon-phosphorus ancillary and chromophoric chelates, synthetic method of preparing the same and phosphorescent organic light emitting diode thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2013-10-15 | — | — | US | disclosed |
| WO-2013057069-A1 | POLYCYCLIC AROMATIC POLYAMINES AND METHODS FOR PRODUCTION THEREOF | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-04-25 | — | — | WO | disclosed |
| EP-2103595-A1 | Method for producing di and polyamines of diphenylmethane series | Bayer MaterialScience AG (DE) | 2009-09-23 | — | — | EP | disclosed |
| US-20090209756-A1 | Emissive transition-metal complexes with both carbon-phosphorus ancillary and chromophoric chelates, synthetic method of preparing the same and phosphorescent organic light emitting diode thereof | NATIONAL TSING HUA UNIVERSITY (TW) | 2009-08-20 | — | — | US | disclosed |
| CN-101443356-A | Neuromedin U receptor agonists and uses thereof | MERCK & CO INC (US) | 2009-05-27 | — | — | CN | disclosed |
| US-20080241280-A1 | Usage of the Plant of Genus Ampelopsis and Extracts Thereof For Manufacture of Medicament and Functional Food | BRIGHT FUTURE PHARMACEUTICAL LABORATORIES LIMITED (CN) | 2008-10-02 | — | — | US | disclosed |
| CN-100337661-C | Application of ampelopsis plant and extract thereof in preparation of medicines and health products | AUMEI PHARMACEUTICAL FACTORY C (HK) | 2007-09-19 | — | — | CN | disclosed |
| EP-1767212-A1 | USAGE OF THE PLANT OF GENUS AMPELOPSIS AND EXTRACTS THEREOF FOR MANUFACTURE OF MEDICAMENT AND FUNCTIONAL FOOD | Bright Future Pharmaceutical Laboratories Limited (CN) | 2007-03-28 | — | — | EP | disclosed |
| CN-1706426-A | Application of ampelopsis plant and extract thereof in preparation of medicines and health products | AUMEI PHARMACEUTICAL FACTORY C (HK) | 2005-12-14 | — | — | CN | disclosed |
| CN-1617718-A | N-aryl-N'-arylcycloalkyl-urea derivatives as MCH antagonists for the treatment of obesity | SCHERING CORP (US) | 2005-05-18 | — | — | CN | disclosed |
| CN-1177581-C | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-12-01 | — | — | CN | disclosed |
| CN-1265583-A | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols | BOEHRINGER INGELHEIM PHARMA (DE) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209756-A1 | Emissive transition-metal complexes with both carbon-phosphorus ancillary and chromophoric chelates, synthetic method of preparing the same and phosphorescent organic light emitting diode thereof | ORC3, EML4, NCL | SIGMAR1 569/4885NPC1 1377/4885RAB9A 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.